Nipro

Nipro EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nipro (8086.T) as of Oct 8, 2026 is 37.63 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 26.60 B JPY — a change of 41.45% (higher).

EBITDA

37.63 BJPY

YoY

41.45%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nipro is 2026 37.63 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nipro was 2025 26.60 B JPY. It decreases by 41.45% higher compared to the previous year.

The Nipro EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
23.83 B JPY
Jan 1, 2020
26.42 B JPY
Jan 1, 2021
27.63 B JPY
Jan 1, 2022
23.88 B JPY
Jan 1, 2023
17.73 B JPY
Jan 1, 2024
22.34 B JPY
Jan 1, 2025
26.60 B JPY
Jan 1, 2026
37.63 B JPY
The Nipro EBITDA history
YEAREBITDAYoY
37.63 BJPY+41.45%
26.60 BJPY+19.09%
22.34 BJPY+25.97%
17.73 BJPY-25.77%
23.88 BJPY-13.55%
27.63 BJPY+4.57%
26.42 BJPY+10.88%
23.83 BJPY-11.74%
27.00 BJPY-6.26%
28.80 BJPY+14.82%
25.08 BJPY+51.37%
16.57 BJPY+34.84%
12.29 BJPY—
Access this data via the Eulerpool API

Nipro Stock analysis

What does Nipro do? Nipro Corp is a Japanese company that was originally founded under the name Niki Shoji. The company was established in 1954 and initially produced steel pipes and accessories. In 1964, the company changed its name to Nipro Corp and expanded its business to the production of medical devices and instruments. Since then, Nipro Corp has become a major player in the global market for medical products and services. The business model of Nipro Corp is based on the design, manufacturing, and sale of a wide range of medical products, including dialysis machines, artificial organs, blood glucose meters, and infusion devices. The company is also active in the pharmaceutical and healthcare industries, offering various related services such as clinical trials. Nipro Corp is divided into various divisions, including Nipro Medical Corporation, which produces and sells the company's medical product range. This division is divided into three departments: dialysis technology, transfusion and infusion department, and the artificial organs department, which includes various products such as heart-lung machines and artificial kidneys. Another important division is Nipro Pharma Corporation, which focuses on the development, manufacturing, and sale of pharmaceuticals. The company has a strong presence in this division in the Asian market and is currently expanding into Europe and the United States. Another important area in which Nipro Corp is active is the manufacturing of glass and plastic products, particularly glass ampoules for storing medications and plastic products for medical use. In addition to its main business areas, Nipro Corp also offers a wide range of products and services for environmental technology, the semiconductor industry, and the electronics industry. The company is also involved in the production of solar energy products and has filed various patents in this field. Innovation and quality control are two important focuses of Nipro Corp. The company is heavily dedicated to researching and developing new products and technologies, as well as building strong business relationships with its customers. One of the key strategies of the company is to align its research and development activities with the needs of its customers and end-users to ensure that its products meet their requirements and expectations. Another focus of Nipro Corp is quality assurance and control. The company has a strict quality management system that is applied in all stages of the manufacturing process to ensure that its products meet the highest international standards. Overall, Nipro Corp has become a major player in the global market for medical products and services. With its wide range of products and services, focus on innovation and quality, and strong presence in the Asian market, the company is in a strong position to continue growing and evolving. Nipro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nipro stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nipro is 37.63 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nipro changed from 26.60 B JPY to 37.63 B JPY, representing a 41.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nipro since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nipro historically and in real time.

Access this data via the Eulerpool API

Income Statement — Nipro

All Key Metrics — Nipro